Auson Pharma (US), a wholly‑owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026 that it has signed an exclusive licensing agreement with Eton Pharmaceuticals (NASDAQ: ETON), granting the latter the rights to develop and commercialize timolol gel (ASN001) in the North American market.
Deal Milestone
Item
Detail
Licensor
Auson Pharma (US) — wholly‑owned subsidiary of Shanghai Auson Pharmaceuticals
Licensee
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
Product
ASN001 — innovative topical timolol gel
Indication
Infantile hemangioma
Territory
North America
Rights Granted
Exclusive development and commercialization
Signing Date
6 Aug 2026
Regulatory Plan
NDA submission to the U.S. FDA in H2 2027; approval expected in 2028
Product Profile & Formulation
Modality: Innovative topical gel formulation of timolol, a beta‑blocker with established use in vascular lesions
Formulation Differentiator: Contains no transdermal enhancers, specifically designed to localize drug activity at the lesion while minimizing systemic absorption
Target Population:Infants with infantile hemangioma — a population where systemic exposure safety margins are critical
Clinical Evidence – Pivotal Registration Studies
Endpoint
Result
Significance
12‑Week Steady‑State Median Plasma Concentration (TID dosing)
109 pg/mL
Substantially lower than systemic exposure following ocular administration of timolol eye drops
12‑Week Steady‑State Median Plasma Concentration (BID dosing)
72.7 pg/mL
Further reduced exposure with twice‑daily regimen
Overall Profile
Favorable safety alongside excellent efficacy
Pivotal registration studies completed
Regulatory Timeline & First‑Mover Potential
Milestone
Timing
NDA submission (U.S. FDA)
Second half of 2027
Expected approval
2028
Market Position
Potential first topical formulation approved for the treatment of infantile hemangioma in the United States
Market Impact & Outlook
Unmet Need in Pediatric Dermatology: Infantile hemangioma is the most common benign tumor of infancy; current U.S. treatment relies on oral propranolol, which carries systemic beta‑blockade risks in infants. A topical, enhancer‑free formulation addresses a significant safety gap.
First‑to‑Market Opportunity: No topical formulation is currently approved in the U.S. for infantile hemangioma — approval of ASN001 would establish a new product category.
Portfolio Fit for Eton: The license adds a differentiated pediatric dermatology asset to Eton Pharmaceuticals’ rare‑disease and specialty portfolio, with a defined regulatory runway to 2028.
Global Strategy for Auson: The North American out‑licensing extends Shanghai Auson Pharmaceuticals’ international footprint, pairing its China‑developed asset with an established U.S. commercial platform.
Forward‑Looking Statements This brief contains forward‑looking statements regarding NDA submission timing, FDA approval, and commercialization of ASN001. Actual results may differ due to risks including regulatory review outcomes, manufacturing scale‑up, market adoption, and competitive dynamics.-Fineline Info & Tech
By Fineline Cube